ENTA

7.6204.51%
MG

Mark G. Foletta

Lead Independent Director

Mr. Mark G. Foletta, CPA, is Lead Independent Director at DexCom, Inc. since November 2015 and served as its Interim Chairman from September 14, 2025 until March 2, 2026. He had been an Independent Board member of DexCom, Inc. since November 19, 2014. Mr. Foletta has been an Independent Director of AMN Healthcare Services Inc. since December 10, 2012 and serves as its Independent Chairman since May 2, 2025. He is an Independent Director at Enanta Pharmaceuticals, Inc. since June 29, 2020. He had been Chief Financial Officer and Executive Vice President of Tocagen Inc. since February 2017 until June 2020. He was a Consultant of Biocept, Inc. since September 2016. He is a Co-Owner of Foletta Family Trust. He serves as the President and Treasurer of Amylin Ohio LLC. He was Executive Vice President and Chief Financial Officer of Forte Biosciences, Inc. He served as the Interim Chief Financial Officer of Biocept, Inc. from August 30, 2015 to July 27, 2016. He is a seasoned financial executive with corporate experience. He has experience in financial, operational and governance leadership roles in the pharmaceutical and biotechnology industry. He served as an Advisor to Chief Executive Officer and Board at Islet Sciences, Inc. from July 15, 2013 to July 30, 2013. He served as a Senior Vice President of Finance at Amylin Pharmaceuticals Inc. (also known as, Amylin Pharmaceuticals, LLC) from March 2006 to August 2012 and also served as its Chief Financial Officer from March 2000 to August 2012 and Principal Accounting Officer until October 2012. He served as a Vice President of Finance at Amylin Pharmaceuticals Inc. from March 2000 to March 2006. He served as Principal of Triton Acquisition Corp (Triton Group Management, Inc.) from 1997 to 2000. From 1986 to 1997, Mr. Foletta held a number of management positions with InterMark Inc. and Triton Group Ltd. from 1986 to 2000. He served as the Chief Financial Officer and Senior Vice President of Triton Group, Ltd. since June 1994 and served as its Corporate Secretary since 1992. From 1982 to 1986, he was with Ernst & Young and served as its Audit Manager. He served as a Vice President and Corporate Controller of Triton Group Ltd. and InterMark, Inc. from 1991 to June 1994. He served as a Vice President at Pharmatek Laboratories, Inc. He has been a Director of ViaCyte, Inc. since December 19, 2013. He served as an Independent Director of Regulus Therapeutics Inc. from January 2013 to June 1, 2018. He serves as a Director of Mission West Properties and Pharmatek Laboratories, Inc. He served as a Director of Anadys Biosciences Corporation from January 27, 2014 to November 10, 2014. He served as an Independent Director of Anadys Pharmaceuticals Inc. from September 6, 2005 to November 23, 2011. He served as a Director of Triton Group Ltd. since February 1996. He is a member of the Corporate Directors Forum. Mr. Foletta holds a B.A. in Business Economics from the University of California, Santa Barbara in 1982. He is a Certified Public Accountant accreditation in 1985. He is a member of the Financial Executives Institute.

Positions